Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153927 | 0.88 | CYP3A4 (0.58) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL2203125 | 0.85 | CYP3A4 (0.66) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL1012409 | 0.85 | CYP3A4 (0.51) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| Hydrochloric Acid SCHEMBL4299984 | 0.84 | CYP3A4 (0.50) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL1012543 | 0.84 | KDM4E (0.51) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL347917 | 0.81 | CYP3A4 (0.51) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL28390127 | 0.81 | CYP3A4 (0.51) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL14193660 | 0.81 | ABCG2 (0.50) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL9559998 | 0.81 | CYP3A4 (0.47) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 | |
| SCHEMBL15525890 | 0.80 | CYP3A4 (0.50) | CYP3A4USP2MAPK1SMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906530-B1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | ALBEMARLE CORP (US) | 2018-01-03 | — | — | EP | claimed |
| CN-104918912-B | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds | 阿尔比马尔公司 | 2017-02-22 | — | — | CN | claimed |
| US-9346743-B2 | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds | ALBEMARLE CORPORATION (US) | 2016-05-24 | — | — | US | claimed |
| US-20160102046-A1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | ALBEMARLE CORPORATION (US) | 2016-04-14 | — | — | US | claimed |
| EP-2906530-A1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | Albemarle Corporation (US) | 2015-08-19 | — | — | EP | claimed |
| WO-2014062428-A1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | ALBEMARLE CORPORATION (US) | 2014-04-24 | — | — | WO | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| CN-115710202-B | Preparation method and application of apataone key intermediate | 江西同和药业股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-4137325-A | Antisecretory oxamic acid esters | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-01-30 | — | — | US | disclosed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4054661-A | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054666-A | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054657-A | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4036837-A | 2 Alkoxyoxamoyl-pyrazines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | CYP3A4 4885/4885USP2 2157/4885MAPK1 2954/4885 |
| US-20160102046-A1 | PROCESSES FOR THE SYNTHESIS OF 2-AMINO-4,6-DIMETHOXYBENZAMIDE AND OTHER BENZAMIDE COMPOUNDS | ALKBH3, ALKBH2, ALKBH1 | CYP3A4 175/4885USP2 1015/4885MAPK1 2061/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | CYP3A4 4868/4885USP2 3140/4885MAPK1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.